LOS OSOS, Calif., July 14, 2015 /PRNewswire/ -- Discovery Life Sciences, Inc., a provider of essential clinical research products and services to the Life Sciences industry announced today that it has launched Magellan – an innovative online ordering platform for ready-to-deliver Human Biospecimens designed for Biopharmaceutical, Biotechnology and Medical Device companies who seek to validate the performance of new diagnostic tests, detection technologies and instrument platforms in clinical and analytical development.
The Magellan platform will have an early focus on Infectious Disease: Viral Hepatitis, Tuberculosis, HIV/AIDS, Flu and other Respiratory viruses, but is also rapidly expanding to include specimens used in Cancer, Fetal- Maternal Health, Cardiac, Metabolic and Autoimmune Disease clinical research. Finalized research partnerships with Clinical Laboratories, Medical Centers, Hospital Networks and Principal Investigators worldwide will also soon contribute samples for Inflammatory, Endocrine and other chronic and acute disease conditions - including Tropical diseases such as Malaria, Leishmaniasis and Dengue Fever.
"Obtaining the proper informed consent, protecting patient confidentiality and ensuring sample integrity for these unique Human Biospecimens can be an early bottleneck in the clinical development process especially with the timelines and delays associated with implementing prospective clinical research programs. With Magellan, we're reinforcing our commitment to helping our Client Companies, Clinical Partners and Research Scientists around the world rapidly translate their biomarker research from early stage discovery to the reality of the clinical marketplace," says Steven Raia, a Founder and Chief Business Officer of Discovery Life Sciences, Inc.
About Discovery Life Sciences, Inc. (www.discoverylifesciences.com) Established in 2004, DLS, Inc. is a leading global provider of clinical research products and services to the Life Science industry that enables expedited analytical and clinical development of novel and existing diagnostic biomarker tests, instrument platforms and detection systems.
SOURCE Discovery Life Sciences, Inc.